JP6951318B2 - 融合ポリペプチドおよび使用方法 - Google Patents

融合ポリペプチドおよび使用方法 Download PDF

Info

Publication number
JP6951318B2
JP6951318B2 JP2018500911A JP2018500911A JP6951318B2 JP 6951318 B2 JP6951318 B2 JP 6951318B2 JP 2018500911 A JP2018500911 A JP 2018500911A JP 2018500911 A JP2018500911 A JP 2018500911A JP 6951318 B2 JP6951318 B2 JP 6951318B2
Authority
JP
Japan
Prior art keywords
seq
fusion polypeptide
fgf18
amino acid
fgf17
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018500911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524005A5 (enExample
JP2018524005A (ja
Inventor
ホンユー リウ，
ホンユー リウ，
ミンジ ジャオ，
ミンジ ジャオ，
ヘトン ソン，
ヘトン ソン，
Original Assignee
プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド
プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド, プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド filed Critical プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド
Publication of JP2018524005A publication Critical patent/JP2018524005A/ja
Publication of JP2018524005A5 publication Critical patent/JP2018524005A5/ja
Application granted granted Critical
Publication of JP6951318B2 publication Critical patent/JP6951318B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018500911A 2015-07-15 2016-07-15 融合ポリペプチドおよび使用方法 Active JP6951318B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/084133 2015-07-15
CNPCT/CN2015/084133 2015-07-15
PCT/CN2016/090110 WO2017008758A1 (en) 2015-07-15 2016-07-15 Fusion polypeptides and methods of use

Publications (3)

Publication Number Publication Date
JP2018524005A JP2018524005A (ja) 2018-08-30
JP2018524005A5 JP2018524005A5 (enExample) 2019-08-15
JP6951318B2 true JP6951318B2 (ja) 2021-10-20

Family

ID=57756671

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018500911A Active JP6951318B2 (ja) 2015-07-15 2016-07-15 融合ポリペプチドおよび使用方法

Country Status (5)

Country Link
US (2) US11020454B2 (enExample)
EP (2) EP3957654A1 (enExample)
JP (1) JP6951318B2 (enExample)
CN (1) CN107849151B (enExample)
WO (1) WO2017008758A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020454B2 (en) 2015-07-15 2021-06-01 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5728546A (en) * 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
UA75316C2 (uk) * 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US7470665B2 (en) * 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
IL139380A0 (en) * 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7414019B2 (en) * 2002-10-04 2008-08-19 Auckland Uniservices Limited FGF-8 methods of use
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
KR20080105096A (ko) 2006-02-28 2008-12-03 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 치근형성 촉진제 및 치근형성 촉진방법
NZ574216A (en) * 2006-08-25 2011-11-25 Ares Trading Sa Treatment of cartilage disorders with fgf-18
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
US20100286042A1 (en) * 2007-10-12 2010-11-11 National Institute Of Advanced Industrial Science And Technology Medicinal Composition Containing Highly Functionalized Chimeric Protein
CA2777717C (en) 2009-10-15 2021-05-25 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
WO2012038953A2 (en) * 2010-09-21 2012-03-29 Hepacore Ltd. Fgf-18 truncated variants having increased receptor specificity and uses thereof
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9421245B2 (en) * 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US11020454B2 (en) 2015-07-15 2021-06-01 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use

Also Published As

Publication number Publication date
EP3322736A1 (en) 2018-05-23
EP3957654A1 (en) 2022-02-23
EP3322736B1 (en) 2021-09-01
US11020454B2 (en) 2021-06-01
WO2017008758A1 (en) 2017-01-19
CN107849151B (zh) 2022-05-24
CN107849151A (zh) 2018-03-27
EP3322736A4 (en) 2019-02-20
JP2018524005A (ja) 2018-08-30
US20180200333A1 (en) 2018-07-19
US20210322516A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
Song et al. Sensing of microbial molecular patterns by Toll‐like receptors
Ince et al. Secretion of flagellar proteins by the Pseudomonas aeruginosa type III secretion-injectisome system
JP2016074655A (ja) 修飾毒素
KR102944792B1 (ko) 죽상동맥경화증 및 관련 질환을 예방 및 치료하기 위한 방법 및 조성물
CN106470707A (zh) 用于口服递送生物活性货物的cholix毒素衍生的融合分子
JP6730926B2 (ja) 融合ポリペプチドおよび使用方法
US20210322516A1 (en) Fusion polypeptides and methods of use
EP2580231A1 (en) Peptides, constructs and uses therefor
US20230242615A1 (en) Fusion polypeptide
EP1326628B1 (en) Chemokine mutants in the treatment of multiple sclerosis
JP7712982B2 (ja) 融合ポリペプチドおよび使用方法
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
WO2012122941A1 (zh) 抗乙型肝炎病毒x蛋白多肽药物
US20240294587A1 (en) K-ras inhibitor
JP6758022B2 (ja) 血管内皮細胞増殖因子受容体阻害ペプチド
US20220275049A1 (en) Antigenic polypeptides and methods of use thereof
JP2022514474A (ja) がん処置
JP2018524005A5 (enExample)
JP2005278472A (ja) オーロラｂ結合因子ｉｎｃｅｎｐ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210810

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210811

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210924

R150 Certificate of patent or registration of utility model

Ref document number: 6951318

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250